Christina Voelkel-Johnson Biography Publications JoVE Articles Christina Voelkel-Johnson has not added a biography. If you are Christina Voelkel-Johnson and would like to personalize this page please email our Author Liaison for assistance. Publications Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-associated Primary Effusion Lymphoma Molecular Cancer Therapeutics. Oct, 2013 | Pubmed ID: 24140934 Inner Ear Supporting Cells Protect Hair Cells by Secreting HSP70 The Journal of Clinical Investigation. Aug, 2013 | Pubmed ID: 23863716 Histone Deacetylase Inhibitors Restore Cell Surface Expression of the Coxsackie Adenovirus Receptor and Enhance CMV Promoter Activity in Castration-resistant Prostate Cancer Cells Prostate Cancer. 2012 | Pubmed ID: 22288017 TRAIL-mediated Signaling in Prostate, Bladder and Renal Cancer Nature Reviews. Urology. Aug, 2011 | Pubmed ID: 21670755 T Cells Expanded in Presence of IL-15 Exhibit Increased Antioxidant Capacity and Innate Effector Molecules Cytokine. Aug, 2011 | Pubmed ID: 21602054 Adenoviral Infectivity of Exfoliated Viable Cells in Urine: Implications for the Detection of Bladder Cancer BMC Cancer. 2011 | Pubmed ID: 21569442 Sorafenib Activates CD95 and Promotes Autophagy and Cell Death Via Src Family Kinases in Gastrointestinal Tumor Cells Molecular Cancer Therapeutics. Aug, 2010 | Pubmed ID: 20682655 Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells Through a Ca(2+)-de Novo Ceramide-PP2A-reactive Oxygen Species-dependent Signaling Pathway Cancer Research. Aug, 2010 | Pubmed ID: 20631069 17-allylamino-17-demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells Via Ca2+-dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species Molecular Cancer Therapeutics. May, 2010 | Pubmed ID: 20442308 Polymer-enhanced Adenoviral Transduction of CAR-negative Bladder Cancer Cells Molecular Pharmaceutics. Sep-Oct, 2009 | Pubmed ID: 19655763 Inhibition of Superoxide Generation Upon T-cell Receptor Engagement Rescues Mart-1(27-35)-reactive T Cells from Activation-induced Cell Death Cancer Research. Aug, 2009 | Pubmed ID: 19638595 Oxidative Stress Sensitizes Bladder Cancer Cells to TRAIL Mediated Apoptosis by Down-regulating Anti-apoptotic Proteins The Journal of Urology. Sep, 2009 | Pubmed ID: 19625063 Oxidative Stress and Lymphocyte Persistence: Implications in Immunotherapy Advances in Cancer Research. 2009 | Pubmed ID: 19595310 The Role of Protein Synthesis in Cell Cycling and Cancer Molecular Oncology. Dec, 2009 | Pubmed ID: 19546037 Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-dependent and -independent Mechanisms Molecular Pharmacology. Aug, 2009 | Pubmed ID: 19483104 MDA-7/IL-24-induced Cell Killing in Malignant Renal Carcinoma Cells Occurs by a Ceramide/CD95/PERK-dependent Mechanism Molecular Cancer Therapeutics. May, 2009 | Pubmed ID: 19417161 Cancer Biology & Therapy. Jan, 2009 | Pubmed ID: 19127121 Transformation, Translation and TRAIL: an Unexpected Intersection Cytokine & Growth Factor Reviews. Apr, 2008 | Pubmed ID: 18353705 Doxorubicin Generates a Proapoptotic Phenotype by Phosphorylation of Elongation Factor 2 Free Radical Biology & Medicine. Nov, 2007 | Pubmed ID: 17893044 Illuminating TRAIL Gene Therapy Cancer Biology & Therapy. Nov, 2006 | Pubmed ID: 17204862 Targeting the Short Form of CFLIP by RNA Interference is Sufficient to Enhance TRAIL Sensitivity in PC3 Prostate Carcinoma Cells Cancer Biology & Therapy. Dec, 2006 | Pubmed ID: 17106251 Resistance to TRAIL is Associated with Defects in Ceramide Signaling That Can Be Overcome by Exogenous C6-ceramide Without Requiring Down-regulation of Cellular FLICE Inhibitory Protein Molecular Cancer Therapeutics. Sep, 2005 | Pubmed ID: 16170023 Doxorubicin Increases the Effectiveness of Apo2L/TRAIL for Tumor Growth Inhibition of Prostate Cancer Xenografts BMC Cancer. Jan, 2005 | Pubmed ID: 15638938 In Vitro Efficacy of Fas Ligand Gene Therapy for the Treatment of Bladder Cancer Cancer Gene Therapy. Jan, 2005 | Pubmed ID: 15514684 Enhanced Apoptosis of Glioma Cell Lines is Achieved by Co-delivering FasL-GFP and TRAIL with a Complex Ad5 Vector Cancer Gene Therapy. Nov, 2003 | Pubmed ID: 14605667 An Antibody Against DR4 (TRAIL-R1) in Combination with Doxorubicin Selectively Kills Malignant but Not Normal Prostate Cells Cancer Biology & Therapy. May-Jun, 2003 | Pubmed ID: 12878867 Doxorubicin Pretreatment Sensitizes Prostate Cancer Cell Lines to TRAIL Induced Apoptosis Which Correlates with the Loss of C-FLIP Expression Cancer Biology & Therapy. Sep-Oct, 2002 | Pubmed ID: 12496481 Resistance of Prostate Cancer Cells to Soluble TNF-related Apoptosis-inducing Ligand (TRAIL/Apo2L) Can Be Overcome by Doxorubicin or Adenoviral Delivery of Full-length TRAIL Cancer Gene Therapy. Feb, 2002 | Pubmed ID: 11857034 An Orthotopic Bladder Cancer Model for Gene Delivery Studies JoVE 50181 Medicine Dissektion af voksne mus Utricle og adenovirus-medieret støtte-celleinfektion Carlene S. Brandon1, Christina Voelkel-Johnson2, Lindsey A. May3, Lisa L. Cunningham3 1Department of Pathology and Laboratory Medicine, Medical University of South Carolina, 2Department of Microbiology & Immunology, Medical University of South Carolina, 3National Institute on Deafness and Other Communication Disorders, National Institutes of Health JoVE 3734 Neuroscience
Dissektion af voksne mus Utricle og adenovirus-medieret støtte-celleinfektion Carlene S. Brandon1, Christina Voelkel-Johnson2, Lindsey A. May3, Lisa L. Cunningham3 1Department of Pathology and Laboratory Medicine, Medical University of South Carolina, 2Department of Microbiology & Immunology, Medical University of South Carolina, 3National Institute on Deafness and Other Communication Disorders, National Institutes of Health JoVE 3734 Neuroscience
